REFERENCES
1. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018;2:1046-53.
2. Chen M, Liu J, Wang X, et al. Diagnosis for Chinese patients with light chain amyloidosis: a scoping review. Ann Med 2023;55:2227425.
3. Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 2017;129:2111-9.
4. Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood 2020;135:1541-7.
5. Ren G, Guo J, Zhao L, et al. Efficacy and safety of daratumumab in treatment of relapsed/refractory systemic light chain amyloidosis. J Nephro Dialy Transplant 2021;30:205-10. Available from: http://www.njcndt.com/EN/abstract/abstract10520.shtml [Last accessed on 26 Dec 2022].
6. Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood 2020;135:1517-30.
